TMRDC Banner

pharma market research - the original one-stop pharmaceutical information shop

PHARMA MARKET RESEARCH STUDIES


Long Term Care and Nursing Home Information Systems Market Shares, Strategies, and Forecasts, Worldwide, 2010 to 2016


Long Term Care and Nursing Home Information Systems Market Shares, Strategies, and Forecasts, Worldwide, 2010 to 2016


Stem Cell Markets


Point of Care Diagnostic Testing World Markets -


Portable and Transport Ventilator Market Shares Strategies, and Forecasts, Worldwide, 2010 to 2016


Portable and Transport Ventilator Market Shares Strategies, and Forecasts, Worldwide, 2010 to 2016


Major Pharmaceutical & Biotechnology Companies of the World 2010


Epigenomics: Emerging Opportunities in Biomarkers, Diagnostics and Therapeutics -



Pilot Project Shows Promise for Type II Diabetics


News Article
Published: March 2005
Sector: Press Release

HUTCHINSON, Kan., March 28 /PRNewswire-FirstCall/ -- HEE Corporation, Inc. (Pink Sheets: HCCF), the exclusive international distributor of HPB-84, a nutraceutical developed in India, provided further information on the Pilot Project currently underway.

Of the nine individuals who started the 12-week pilot program, four have now completed their mid-point lab studies. While it is too early to draw any conclusions from the pilot project, the researchers have reported that several patients have needed to reduce their oral diabetic medications or insulin and all nine patients have tolerated HPB-84 well. The twelve week Pilot Project is to be completed by the end of May with a final report due before the end of June 2005.

HEE President, Radley Brooks said, "With the Pilot Project testing at PRN, the patients are given a titration schedule where they increase the number of HPB-84 tablets taken each day. This is being done to give us the information needed to determine an effective dose based on the weight of individual participants. This is much different than the way Ron and Stan (two of the original users of HPB-84) were given HPB-84 overseas. They started at the maximum dose and had to hold raw, loose herbs in their cheek and swallow the juices generated for 30 minutes three times a day. As a result, their improvement occurred over a shorter period of time. I have little doubt the HPB-84 tablet will generate the same positive results with other people, although it may take longer given the administration through the digestive system. It will certainly taste better, be more acceptable to the diabetic population, and meets FDA requirements for marketing nutraceuticals (FDA frowns upon sublingual administration)."

"HEE Corp continues to generate solid marketplace interest in HPB-84, a nutraceutical developed specifically for Type II Diabetics. We continue to receive requests from people all over the country, as well as internationally, who want to be able to purchase HPB-84," explains Radley Brooks, HEE President. "We have conducted a thorough review of the Company's business and developed what we believe is the best way to bring HPB-84 to the marketplace."

With this in mind, the company has been developing an e-commerce website to sell HPB-84. HEE is committed to having the e-commerce site available to the general public as quickly as possible. Although no date has been set for the website to be operational, HEE Corporation expects it to be available within the next few weeks and is currently adding potential customers to a waiting list until the site is operational. Please contact HEE Corporation at 620-663-3333 to be placed on the waiting list of HEE's HPB-84.

This press release is provided in good-faith by Chiltern Magazine Services Ltd ("CMS") as a service to users. Whilst every care is taken in sourcing and preparing material included here, any error or incorrect content cannot form the basis for any legal action against the site-owner. Users are advised to check the accuracy of any statements before relying upon them. Likewise, any forward-looking statements made by the author of the press release should be treated as such.

For full details, please email keithw@cmsinfo.com

Home | About | Terms | Privacy


Office Address: Chiltern Magazine Services Ltd., P&A House, Chesham, Bucks. HP5 3HB, England.

Telephone: UK +44 (0) 1494 771734 Fax: +44 (0) 01494 778994 e-mail: keithw@cmsinfo.com

Telephone: USA +(1) 508 861 0401 Fax: +(1) 508 861 0401

Registered Office: 2a Altons House Office Park, Gatehouse Way, Aylesbury, HP19 3XU, UK

Registered in England and Wales No. 3240740 VAT No. GB 685 4343 10

CMSInfo (Chiltern Magazine Services Ltd.) is a company registered at Companies House in England and Wales (Company No. 3240740).
CMSInfo is also registered in accordance with the Data Protection Act 1998 (registration number R0094104).
Terms and Conditions